Entering text into the input field will update the search result below

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2019 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2019 Earnings Conference Call March 5, 2020 4:30 PM ET

Company Participants

Zack Kubow - Investor Relations, Pure Communications

Richard Miller - President and Chief Executive Officer

Leiv Lea - Chief Financial Officer

Conference Call Participants

Tony Butler - ROTH Capital Partners

Mara Goldstein - Mizuho

Jeet Mukherjee - Jefferies


Good afternoon, ladies and gentlemen. Thank you for standing by and welcome to the Corvus Pharmaceuticals Fourth Quarter 2019 Business Update and Financial Results Webcast. Today's conference is being recorded. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time.

It is now my pleasure to turn the call over to Zack Kubow of Pure Communications. Please go ahead, sir.

Zack Kubow

Thank you, operator, and good afternoon, everyone. Thanks for joining us for the Corvus Pharmaceuticals fourth quarter 2019 business update and financial results conference call.

On the call to discuss the results and business highlights for the fourth quarter 2019 are Richard Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; and Mehrdad Mobasher, Chief Medical Officer. The executive team will open the call with some prepared remarks, followed by a question-and-answer period.

I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Forward-looking statements are based on estimates and assumptions as of today, and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in Corvus' quarterly report on Form 10-Q filed with the SEC on October 29, 2019 and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements

Recommended For You

Comments (2)

sbrncra profile picture
Corvus has been partnering with Genetech in research studies
sbrncra profile picture
Total cost 2020 expected high end 42 mil......so..... 78 mil cash....so new announcement for raising 50 mil...so either the trial(s) are being quickly move to a large scale...or....a buyout wants additional funding to carry them before & after a takeout
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.